GUTS

Fractyl Health Inc

May 18 • 02:08PM ET

0.7718

-0.0888 -10.31 %

Healthcare • Biotechnology • USA • Micro • NASD

May 13, 8:31 PMQ1 earnings beat, Rejuva trial authorization, and reaffirmed 2026 catalysts drive 29% GUTS surge.

Peers: ORMP ALT RZLT VANI LCTX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.50	Insider Own	17.58%	Shs Outstand	158.65M	Perf Week	0.37%
Market Cap	122.45M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	0.04%	Shs Float	128.05M	Perf Month	35.55%
Enterprise Value	120.10M	PEG	-	EPS next Q	-0.14	Inst Own	36.26%	Short Float	2.35%	Perf Quarter	96.55%
Income	-108.00M	P/S	-	EPS this Y	80.00%	Inst Trans	13.98%	Short Ratio	1.24	Perf Half Y	-31.08%
Sales	0.00M	P/B	5.73	EPS next Y	-38.17%	ROA	-118.41%	Short Interest	3.01M	Perf YTD	-64.92%
Book/sh	0.13	P/C	1.94	EPS next 5Y	43.25%	ROE	-778.33%	52W High	3.03 -74.53%	Perf Year	-54.33%
Cash/sh	0.40	P/FCF	-	EPS past 3/5Y	-11.63% -16.69%	ROIC	-140.16%	52W Low	0.38 104.63%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.55% 10.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.45%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.28	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	56.32	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	4.28	EPS Q/Q	111.98%	SMA20	7.86%	Beta	2.25	Target Price	5.24
Payout	-	Debt/Eq	2.84	Sales Q/Q	-	SMA50	35.23%	Rel Volume	0.88	Prev Close	0.86
Employees	100	LT Debt/Eq	2.60	Earnings	May 12 AMC	SMA200	-31.51%	Avg Volume	2.43M	Price	0.77
IPO	Feb 02, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	137.50% -	Trades		Volume	1,556,781	Change	-10.31%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$2
Sep-15-25	Initiated	H.C. Wainwright	Buy	$9
Aug-28-25	Initiated	Ladenburg Thalmann	Buy	$3.60
Feb-28-24	Initiated	Evercore ISI	Outperform
Feb-27-24	Initiated	Morgan Stanley	Overweight	$18
Feb-27-24	Initiated	BofA Securities	Buy	$26

May-13-26 01:02AM	Fractyl Health Inc (GUTS) Q1 2026 Earnings Call Highlights: Pivotal Trial Progress and ... (GuruFocus.com) +29.20%
May-12-26 04:05PM	Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
May-11-26 07:00AM	Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes (GlobeNewswire)
06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive)
May-05-26 07:00AM	Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference (GlobeNewswire)
09:15AM	Loading…
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire) -5.20%
Mar-25-26 08:30AM	Fractyl Health, Inc. Common Stock Q4 2025 Earnings Call Summary (Moby) +16.17%
Mar-24-26 11:01PM	Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
04:01PM	Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire)
Mar-17-26 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 (GlobeNewswire)
Feb-26-26 07:00AM	Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance (GlobeNewswire) -6.19%
Feb-23-26 09:35AM	Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-29-26 01:48PM	Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product (Benzinga) -68.04%
12:12PM	Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain (MarketBeat)
07:00AM	Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation (GlobeNewswire)
07:00AM	Loading…
Jan-06-26 07:00AM	Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness (GlobeNewswire)
Jan-05-26 07:00AM	Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category (GlobeNewswire) -8.44%
Jan-03-26 06:19AM	Analysts Keep Buy Ratings on Fractyl Health (GUTS) (Insider Monkey)
Dec-31-25 11:12AM	Fractyl Health's REVEAL-1 Study Shows Positive Six-Month Results for Revita in Maintaining Weight and Glycemic Control Post-GLP-1 Use (Insider Monkey)
Dec-15-25 05:45PM	Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones (GlobeNewswire)
Dec-02-25 07:00AM	Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure (GlobeNewswire) +17.95%
Dec-01-25 07:00AM	Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-13-25 12:01AM	Fractyl Health Inc (GUTS) Q3 2025 Earnings Call Highlights: Pioneering Weight Loss Solutions ... (GuruFocus.com)
Nov-12-25 04:05PM	Fractyl Health Reports Third Quarter 2025 Results; Revita Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 (GlobeNewswire)
Nov-05-25 07:00AM	Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 (GlobeNewswire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-17-25 09:59AM	Fractyl Health Unveils Potent Preclinical Data for Dual GIP/GLP-1 Gene Therapy RJVA-002 for Obesity (Insider Monkey)
Oct-07-25 07:00AM	Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity (GlobeNewswire) -6.80%
Sep-26-25 07:05AM	Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock (GlobeNewswire) +32.67%
07:00AM	Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation (GlobeNewswire)
07:00AM	Loading…
Sep-03-25 07:00AM	Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth (GlobeNewswire)
Aug-13-25 03:12AM	Fractyl Health Inc (GUTS) Q2 2025 Earnings Call Highlights: Financial Discipline and Promising ... (GuruFocus.com)
Aug-12-25 04:05PM	Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-07-25 04:05PM	Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-06-25 04:05PM	Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -45.99%
08:30AM	Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering (GlobeNewswire)
Aug-05-25 04:15PM	Fractyl Health Announces Proposed Public Offering (GlobeNewswire)
04:02PM	Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure (GlobeNewswire)
Jul-29-25 10:23AM	Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS) (Insider Monkey) -7.61%
Jun-23-25 07:40AM	Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy (GlobeNewswire) -24.77%
07:30AM	Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models (GlobeNewswire)
Jun-18-25 07:00AM	Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing (GlobeNewswire)
Jun-13-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.07%
07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire)
Jun-04-25 07:00AM	Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide (GlobeNewswire)
May-19-25 07:00AM	Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes (GlobeNewswire) +25.44%
May-17-25 07:15AM	Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 (GlobeNewswire)
May-13-25 04:05PM	Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -13.28%
May-06-25 07:00AM	Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -7.98%
Apr-28-25 04:30PM	Fractyl Health to Present Compelling Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire)
Apr-02-25 03:34PM	Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025 (Insider Monkey)
Apr-01-25 07:00AM	Fractyl Health Reports Positive Early Data Showing Revita Has Potential to Prevent Weight Regain After GLP-1 Discontinuation (GlobeNewswire) -6.72%
Mar-03-25 04:05PM	Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Feb-24-25 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 (GlobeNewswire)
Feb-12-25 09:35AM	After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS) (Zacks)
Feb-10-25 03:00AM	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments (Pharma Voice)
Jan-31-25 08:01AM	Fractyl Health Announces Increased Focus on Groundbreaking Revita Weight Maintenance and Rejuva Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 (GlobeNewswire) -5.15%
Jan-13-25 07:00AM	Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort (GlobeNewswire) +5.41%
Jan-06-25 09:10AM	Heres Why Fractyl Health, Inc. (NASDAQ:GUTS) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) -6.36%
Dec-12-24 07:00AM	Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-09-24 07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Nov-26-24 07:00AM	Fractyl Health to Participate in the Upcoming December Conferences (GlobeNewswire)
Nov-12-24 04:05PM	Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-24 04:05PM	Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek 2024 (GlobeNewswire) -9.86% -6.25%
07:00AM	Fractyl Health Presented New Analysis from Pooled Data of Revita Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek 2024 (GlobeNewswire)
Oct-29-24 07:00AM	Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 (GlobeNewswire) +23.19%
Oct-28-24 07:00AM	Fractyl Health to Present Compelling Weight Maintenance Data from both Revita and Rejuva Platforms at ObesityWeek 2024 (GlobeNewswire) +16.46%
Sep-24-24 07:00AM	Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-03-24 07:00AM	Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.38%
Aug-12-24 10:53AM	Rising diabetes rates spur growth in weight management solutions (Medical Device Network) +14.61%
Aug-08-24 12:13PM	Fractyl Health touts positive year-long weight loss results for Revita device (Clinical Trials Arena) -6.19%
08:00AM	Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure (GlobeNewswire)
Aug-07-24 07:00AM	Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 (GlobeNewswire) -9.77%
Jul-30-24 07:00AM	Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs (GlobeNewswire)
Jun-25-24 09:02AM	FDA expands Fractyl endoscopy trial to include untreated diabetes patients (Medical Device Network) -9.22%
07:00AM	Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day (GlobeNewswire)
Jun-24-24 06:00AM	Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates (GlobeNewswire) +5.76%
Jun-23-24 01:30PM	Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-29-24 07:00AM	Fractyl Health to Present New Preclinical Obesity Data from Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-20-24 06:00AM	Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 (GlobeNewswire)
May-13-24 08:56PM	GUTS Stock Earnings: Fractyl Health Beats EPS for Q1 2024 (InvestorPlace) +8.52%
04:00PM	Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
11:41AM	Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes (MT Newswires)
06:00AM	Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) (GlobeNewswire)
May-08-24 06:00AM	Fractyl Health to Present at BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-07-24 06:00AM	Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 (GlobeNewswire)
Apr-30-24 08:38AM	Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting (GlobeNewswire)
Apr-17-24 03:10PM	The 3 Most Volatile Stocks for Short-Term Traders: April 2024 (InvestorPlace)
Apr-02-24 08:00AM	Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes (GlobeNewswire) -9.53%
Apr-01-24 07:00AM	Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
06:00AM	Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs (GlobeNewswire)
Mar-12-24 02:06PM	UPDATE -- Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire) -10.34%
08:38AM	Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire)
Mar-03-24 01:13PM	Analysts Bet Big on These Beaten-Down IPO Stocks (TipRanks)
Feb-20-24 08:38AM	Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita Pivotal Clinical Trials (GlobeNewswire)
Feb-01-24 08:08PM	Fractyl Health Announces Pricing of Initial Public Offering (GlobeNewswire)

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Ph.D.Dr. Harith Rajagopalan M.D.

MBAMr. Jay D. Caplan BSEE

General Counsel & Corporate SecretaryMs. Sarah S. Toomey Esq.

CFO & TreasurerMs. Lara Smith Weber

Head of Investor Relations & Corporate DevelopmentMr. Brian Luque

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rajagopalan Harith	Chief Executive Officer	Dec 04 '25	Buy	1.92	10,416	19,999	501,745	Dec 08 07:05 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GUTS

Fractyl Health Inc

Upgrade your Finviz experience